Jason Mattingly, MD
Family Medicine · Cincinnati, OHNPI 1548267826
Payments from drug & device makers
Across 115 payments — averaging $14.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$483
- Novo Nordisk$244
- Dexcom, Inc.$118
- Johnson & Johnson$116
- Amgen$73
- Ironshore Pharmaceuticals Inc.$71
- plus $519 from 18 others
What the payments were for
- Food & beverage$1,622100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 48 | $483 |
| Novo Nordisk | 11 | $244 |
| Dexcom, Inc. | 7 | $118 |
| Johnson & Johnson | 7 | $116 |
| Amgen | 4 | $73 |
| Ironshore Pharmaceuticals Inc. | 4 | $71 |
| Abbott | 3 | $65 |
| Pfizer | 4 | $53 |
| Exact Sciences | 3 | $52 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $46 |
| Lilly USA, LLC | 3 | $37 |
| AstraZeneca | 3 | $36 |
| Bayer | 2 | $32 |
| GSK | 2 | $28 |
| Neurocrine Biosciences, Inc. | 2 | $28 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $22 |
| Lundbeck LLC | 1 | $16 |
| Merck | 1 | $16 |
| Boehringer Ingelheim | 1 | $16 |
| Exelixis Inc. | 1 | $16 |
| Minerva Surgical, Inc | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Mannkind Corporation | 1 | $14 |
| Astellas Pharma US Inc | 1 | $13 |
How this compares
$1,622 in reported general payments places this provider in the 70th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 60 | $68,749 |
| MounjaroTirzepatide | 51 | $58,041 |
| OzempicSemaglutide | 50 | $55,966 |
| EliquisApixaban | 45 | $50,706 |
| JardianceEmpagliflozin | 43 | $48,429 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 45 | $27,557 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $21,835 |
| LinzessLinaclotide | 13 | $18,905 |
| BelsomraSuvorexant | 33 | $18,836 |
| FarxigaDapagliflozin Propanediol | 25 | $15,703 |
| SynjardyEmpagliflozin/Metformin Hcl | 16 | $12,555 |
| NamzaricMemantine Hcl/Donepezil Hcl | 12 | $10,357 |
| Bydureon BciseExenatide Microspheres | 11 | $9,029 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $8,359 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $7,040 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $37 | $126,789111 claims |
| GSKAnoro Ellipta, Trelegy Ellipta, Breo Ellipta, Incruse Ellipta | $28 | $62,55393 claims |
| Boehringer IngelheimJardiance, Synjardy | $16 | $60,98459 claims |
| Novo NordiskOzempic | $244 | $55,96650 claims |
| PfizerEliquis | $53 | $50,70645 claims |
| AbbVieLinzess, Namzaric | $483 | $29,26225 claims |
| MerckBelsomra | $16 | $18,83633 claims |
| AstraZenecaFarxiga | $36 | $15,70325 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Cincinnati
- Michael ButcherCincinnati$18.3M
- Paul NugentCincinnati$4.9M
- Rajesh DavitCincinnati$2M
- Michael HeileCincinnati$272K
- Michael NossCincinnati$265K
- Amy MechleyCincinnati$120K
- Melissa SchroerCincinnati$116K
- William CoxCincinnati$52K
- Frank PerrinoCincinnati$49K
- Sean LyndCincinnati$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.